Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03056690 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Analgesic Efficacy and Safety of ASP0819 in Patients With Fibromyalgia
A Phase 2 study, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 186
- Enrollment target
NCT03056690 is a Phase 2 study that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 186 participants.
The verdict
NCT03056690, a Phase 2 study, has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 186 participants
- Enrollment target
Study Summary
This study assessed analgesic efficacy of ASP0819 relative to placebo as well as the safety and tolerability. This study assessed treatment differences in physical function as well as the improvements in overall subject status (e.g., fibromyalgia symptoms and global functioning) of ASP0819 relative to placebo.
Interventions
- DRUG Placebo
- DRUG ASP0819
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2017-03-20 |
| Est. Completion | 2018-02-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03056690
The ClinicalTrials.gov registry entry for NCT03056690 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Global Development, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03056690 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03056690 about?
NCT03056690 is a clinical study titled "A Study to Assess the Analgesic Efficacy and Safety of ASP0819 in Patients With Fibromyalgia". This study assessed analgesic efficacy of ASP0819 relative to placebo as well as the safety and tolerability. This study assessed treatment differences in physical function as well as the improvements in overall subject status (e.g., fibromyalgia symptoms and global functioning) of ASP0819 relative...
What is the current status of trial NCT03056690?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 186 participants. The study started on 2017-03-20. Estimated completion is 2018-02-27.
What interventions are being tested in trial NCT03056690?
The interventions under investigation include: Placebo (DRUG), ASP0819 (DRUG).
Who is sponsoring clinical trial NCT03056690?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.